JP2013536857A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013536857A5 JP2013536857A5 JP2013527255A JP2013527255A JP2013536857A5 JP 2013536857 A5 JP2013536857 A5 JP 2013536857A5 JP 2013527255 A JP2013527255 A JP 2013527255A JP 2013527255 A JP2013527255 A JP 2013527255A JP 2013536857 A5 JP2013536857 A5 JP 2013536857A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- tetrahydro
- chloro
- methyl
- benzazepine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002552 dosage form Substances 0.000 claims description 73
- 238000000034 method Methods 0.000 claims description 69
- 150000003839 salts Chemical class 0.000 claims description 69
- 239000008194 pharmaceutical composition Substances 0.000 claims description 33
- 230000037221 weight management Effects 0.000 claims description 33
- XTTZERNUQAFMOF-QMMMGPOBSA-N lorcaserin Chemical compound C[C@H]1CNCCC2=CC=C(Cl)C=C12 XTTZERNUQAFMOF-QMMMGPOBSA-N 0.000 claims description 31
- 239000012453 solvate Substances 0.000 claims description 19
- 239000007888 film coating Substances 0.000 claims description 16
- 238000009501 film coating Methods 0.000 claims description 16
- 150000004677 hydrates Chemical class 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
- 235000012054 meals Nutrition 0.000 claims description 12
- VOJUXHHACRXLTD-UHFFFAOYSA-N 1,4-dihydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC(O)=C21 VOJUXHHACRXLTD-UHFFFAOYSA-N 0.000 claims description 11
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 11
- 235000012631 food intake Nutrition 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 206010033307 Overweight Diseases 0.000 claims description 8
- 239000000883 anti-obesity agent Substances 0.000 claims description 8
- 229940125708 antidiabetic agent Drugs 0.000 claims description 8
- 239000003472 antidiabetic agent Substances 0.000 claims description 8
- 229940125710 antiobesity agent Drugs 0.000 claims description 8
- 230000004580 weight loss Effects 0.000 claims description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 6
- 229930195725 Mannitol Natural products 0.000 claims description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 230000037406 food intake Effects 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- 239000000594 mannitol Substances 0.000 claims description 6
- 235000010355 mannitol Nutrition 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
- 230000036186 satiety Effects 0.000 claims description 6
- 235000019627 satiety Nutrition 0.000 claims description 6
- KBRBOQRSMDBFNF-MABWYXAVSA-N (5r)-7-chloro-5-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine;(e)-3-phenylprop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=CC=C1.C[C@H]1CNCCC2=CC=C(Cl)C=C12 KBRBOQRSMDBFNF-MABWYXAVSA-N 0.000 claims description 5
- PSWJLTWGTOAZAY-QRPNPIFTSA-N (5r)-7-chloro-5-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine;2-hydroxy-2-phenylacetic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1.C[C@H]1CNCCC2=CC=C(Cl)C=C12 PSWJLTWGTOAZAY-QRPNPIFTSA-N 0.000 claims description 5
- NKBLAKRCFQQYPG-QRPNPIFTSA-N (5r)-7-chloro-5-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine;hydroiodide Chemical compound I.C[C@H]1CNCCC2=CC=C(Cl)C=C12 NKBLAKRCFQQYPG-QRPNPIFTSA-N 0.000 claims description 5
- FJTNYFLNJZFMAL-LOOJJACZSA-N (e)-but-2-enedioic acid;(5r)-7-chloro-5-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound OC(=O)\C=C\C(O)=O.C[C@H]1CNCCC2=CC=C(Cl)C=C12 FJTNYFLNJZFMAL-LOOJJACZSA-N 0.000 claims description 5
- FJTNYFLNJZFMAL-KZDSSNOQSA-N (z)-but-2-enedioic acid;(5r)-7-chloro-5-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound OC(=O)\C=C/C(O)=O.C[C@H]1CNCCC2=CC=C(Cl)C=C12 FJTNYFLNJZFMAL-KZDSSNOQSA-N 0.000 claims description 5
- KIKNVEPHVFMBHM-JZGIKJSDSA-N C(C1=CC=CC=C1)(=O)O.CC(=O)NC(=O)C.ClC=1C=CC2=C([C@H](CNCC2)C)C1 Chemical compound C(C1=CC=CC=C1)(=O)O.CC(=O)NC(=O)C.ClC=1C=CC2=C([C@H](CNCC2)C)C1 KIKNVEPHVFMBHM-JZGIKJSDSA-N 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 4
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 235000003642 hunger Nutrition 0.000 claims description 4
- ITIHHRMYZPNGRC-QRPNPIFTSA-N lorcaserin hydrochloride Chemical compound Cl.C[C@H]1CNCCC2=CC=C(Cl)C=C12 ITIHHRMYZPNGRC-QRPNPIFTSA-N 0.000 claims description 4
- WRZCAWKMTLRWPR-VSODYHHCSA-N lorcaserin hydrochloride hemihydrate Chemical group O.Cl.Cl.C[C@H]1CNCCC2=CC=C(Cl)C=C12.C[C@H]1CNCCC2=CC=C(Cl)C=C12 WRZCAWKMTLRWPR-VSODYHHCSA-N 0.000 claims description 4
- 230000036470 plasma concentration Effects 0.000 claims description 4
- 201000002859 sleep apnea Diseases 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 19
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- OPWLNUCRCHHDDF-QRPNPIFTSA-N (5r)-7-chloro-5-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine;2,4-dioxo-1h-pyrimidine-6-carboxylic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1.C[C@H]1CNCCC2=CC=C(Cl)C=C12 OPWLNUCRCHHDDF-QRPNPIFTSA-N 0.000 claims 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 7
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 6
- 239000001856 Ethyl cellulose Substances 0.000 description 5
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 5
- 229920001249 ethyl cellulose Polymers 0.000 description 5
- 235000019325 ethyl cellulose Nutrition 0.000 description 5
- ZCKAMNXUHHNZLN-UHFFFAOYSA-N Chlorphentermine Chemical group CC(C)(N)CC1=CC=C(Cl)C=C1 ZCKAMNXUHHNZLN-UHFFFAOYSA-N 0.000 description 3
- 229950007046 chlorphentermine Drugs 0.000 description 3
- HXCXASJHZQXCKK-UHFFFAOYSA-N clortermine Chemical compound CC(C)(N)CC1=CC=CC=C1Cl HXCXASJHZQXCKK-UHFFFAOYSA-N 0.000 description 3
- 229950000649 clortermine Drugs 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical group CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 3
- 229960003105 metformin Drugs 0.000 description 3
- UMWAUEZOGHNSCH-UHFFFAOYSA-N pentorex Chemical compound CC(N)(C)C(C)C1=CC=CC=C1 UMWAUEZOGHNSCH-UHFFFAOYSA-N 0.000 description 3
- 229950000821 pentorex Drugs 0.000 description 3
- 229960003562 phentermine Drugs 0.000 description 3
- 201000009104 prediabetes syndrome Diseases 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- ZRPYKXHZFPGPRZ-UHFFFAOYSA-N 5-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound CC1CNCCC2=CC=CC=C12 ZRPYKXHZFPGPRZ-UHFFFAOYSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40257810P | 2010-09-01 | 2010-09-01 | |
| US61/402,578 | 2010-09-01 | ||
| US40314310P | 2010-09-10 | 2010-09-10 | |
| US61/403,143 | 2010-09-10 | ||
| PCT/US2011/049914 WO2012030927A2 (en) | 2010-09-01 | 2011-08-31 | Modified-release dosage forms of 5-ht2c agonists useful for weight management |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016011493A Division JP2016056211A (ja) | 2010-09-01 | 2016-01-25 | 体重管理のために有用な５−ｈｔ２ｃアゴニストの改変放出剤形 |
| JP2017179402A Division JP2017214437A (ja) | 2010-09-01 | 2017-09-19 | 体重管理のために有用な５−ｈｔ２ｃアゴニストの改変放出剤形 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013536857A JP2013536857A (ja) | 2013-09-26 |
| JP2013536857A5 true JP2013536857A5 (cg-RX-API-DMAC7.html) | 2014-10-16 |
| JP6272695B2 JP6272695B2 (ja) | 2018-01-31 |
Family
ID=44645820
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013527255A Expired - Fee Related JP6272695B2 (ja) | 2010-09-01 | 2011-08-31 | 体重管理のために有用な５−ｈｔ２ｃアゴニストの改変放出剤形 |
| JP2016011493A Pending JP2016056211A (ja) | 2010-09-01 | 2016-01-25 | 体重管理のために有用な５−ｈｔ２ｃアゴニストの改変放出剤形 |
| JP2017179402A Withdrawn JP2017214437A (ja) | 2010-09-01 | 2017-09-19 | 体重管理のために有用な５−ｈｔ２ｃアゴニストの改変放出剤形 |
| JP2019124572A Withdrawn JP2019163336A (ja) | 2010-09-01 | 2019-07-03 | 体重管理のために有用な５−ｈｔ２ｃアゴニストの改変放出剤形 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016011493A Pending JP2016056211A (ja) | 2010-09-01 | 2016-01-25 | 体重管理のために有用な５−ｈｔ２ｃアゴニストの改変放出剤形 |
| JP2017179402A Withdrawn JP2017214437A (ja) | 2010-09-01 | 2017-09-19 | 体重管理のために有用な５−ｈｔ２ｃアゴニストの改変放出剤形 |
| JP2019124572A Withdrawn JP2019163336A (ja) | 2010-09-01 | 2019-07-03 | 体重管理のために有用な５−ｈｔ２ｃアゴニストの改変放出剤形 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20130315994A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3485878A1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP6272695B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20180118801A (cg-RX-API-DMAC7.html) |
| CN (2) | CN103189053A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2011296003B2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3050049A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2704455T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL224829B (cg-RX-API-DMAC7.html) |
| SG (2) | SG10201506874UA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012030927A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013539470A (ja) | 2010-09-01 | 2013-10-24 | アリーナ ファーマシューティカルズ， インコーポレイテッド | ロルカセリンと光学活性な酸との塩 |
| CA2808890A1 (en) | 2010-09-01 | 2012-03-08 | Arena Pharmaceuticals, Inc. | Administration of lorcaserin to individuals with renal impairment |
| CN103189053A (zh) | 2010-09-01 | 2013-07-03 | 艾尼纳制药公司 | 用于体重控制的5-ht2c激动剂的调节释放剂型 |
| CA2808904A1 (en) | 2010-09-01 | 2012-03-08 | Arena Pharmaceuticals, Inc. | Non-hygroscopic salts of 5-ht2c agonists |
| US8399011B1 (en) * | 2012-08-10 | 2013-03-19 | Magnifica Inc. | Oral particle compositions containing a core and an acid-soluble coat |
| CA2886875A1 (en) * | 2012-10-09 | 2014-04-17 | Arena Pharmaceuticals, Inc. | Method of weight management |
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| CA2919213A1 (en) * | 2013-07-29 | 2015-02-05 | Adare Pharmaceuticals, Inc. | Stabilized modified release folic acid derivative composition, its therapeutic use and methods of manufacture |
| EP2868656A1 (en) * | 2013-11-05 | 2015-05-06 | LEK Pharmaceuticals d.d. | Stabilized amorphous lorcaserin hydrochloride |
| EP2924024A3 (en) | 2014-03-21 | 2016-01-20 | Medichem, S.A. | Solid forms of lorcaserin hydrochloride |
| WO2015161730A1 (zh) * | 2014-04-21 | 2015-10-29 | 杭州普晒医药科技有限公司 | 一种氯卡色林共晶及其制备方法、药物组合物和用途 |
| EA022748B1 (ru) * | 2014-06-02 | 2016-02-29 | Делкростон Менеджмент Лимитед | Способы получения двойных солей лоркасерина (варианты), продукты способов, двойные соли, фармацевтические композиции для лечения и/или профилактики нарушений, связанных с ожирением, их применение и способ лечения и/или профилактики нарушений, связанных с ожирением |
| AU2015326472B2 (en) * | 2014-09-29 | 2020-05-28 | Zogenix International Limited | Control system for control of distribution of medication |
| WO2016069875A1 (en) | 2014-10-30 | 2016-05-06 | Arena Pharmaceuticals, Inc. | Compositions and methods for ceasing tobacco smoking |
| US10308611B2 (en) * | 2015-03-24 | 2019-06-04 | Aurobindo Pharma Ltd | Process for the preparation of Lorcaserin hydrochloride |
| US20170174614A1 (en) | 2015-12-22 | 2017-06-22 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
| FI3800177T3 (fi) | 2015-12-22 | 2025-04-29 | Zogenix International Ltd | Fenfluramiinikoostumukset ja menetelmät niiden valmistamiseksi |
| MX391442B (es) * | 2016-08-19 | 2025-03-21 | Arena Pharm Inc | Agonistas y composiciones del receptor 5-ht2c y métodos de uso. |
| EP4201427A1 (en) | 2016-08-24 | 2023-06-28 | Zogenix International Limited | Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same |
| TW202510891A (zh) * | 2017-01-31 | 2025-03-16 | 美商基利科學股份有限公司 | 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型 |
| US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
| EP3733204A4 (en) | 2017-12-27 | 2021-09-15 | Takeda Pharmaceutical Company Limited | THERAPEUTIC AGENT FOR URINARY INCONTINENCE OF STRESS AND FECAL INCONTINENCE |
| US11571397B2 (en) | 2018-05-11 | 2023-02-07 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
| EP3860996A4 (en) | 2018-10-02 | 2022-08-31 | Northwestern University | BETA-CARBOLINES AS POSITIVE ALLOSTERIC MODULATORS OF HUMAN SEROTONIN RECEPTOR 2C (5-HT2C) |
| CA3117868A1 (en) | 2018-11-19 | 2020-05-28 | Zogenix International Limited | Methods of treating rett syndrome using fenfluramine |
| CN110354088A (zh) * | 2019-07-23 | 2019-10-22 | 南京昂谷医药科技有限公司 | 盐酸氯卡色林缓释片及其制备方法 |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| CN113974568B (zh) * | 2021-11-09 | 2024-03-26 | 重庆火后草科技有限公司 | 基于斜率去干扰的睡眠过程的代谢率的计算方法 |
Family Cites Families (142)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2900415A (en) | 1954-12-14 | 1959-08-18 | Lakeside Lab Inc | Synthesized antispasmodic compounds |
| CH498122A (de) | 1968-02-09 | 1970-10-31 | Geigy Ag J R | Verfahren zur Herstellung eines neuen Tetrahydroazepinderivates |
| CH481110A (de) | 1967-02-17 | 1969-11-15 | Geigy Ag J R | Verfahren zur Herstellung von 1,2,4,5-Tetrahydro-3-azepinen |
| GB1268243A (en) | 1968-03-11 | 1972-03-22 | Wallace & Tiernan Inc | 0,2,4,5,-tetrahydro-3h,3-benzazepines |
| US4233217A (en) | 1968-03-11 | 1980-11-11 | Pennwalt Corporation | Substituted 1,2,4,5-tetrahydro-3H, 3 benzazepines |
| FR314F (cg-RX-API-DMAC7.html) | 1968-03-22 | 1970-05-25 | ||
| FR7736M (cg-RX-API-DMAC7.html) | 1968-09-02 | 1970-03-09 | ||
| US3716639A (en) | 1970-03-11 | 1973-02-13 | Ciba Geigy Corp | Anorexigenic tetrahydrobenzazepines |
| US3795683A (en) | 1970-08-19 | 1974-03-05 | Hoffmann La Roche | 2,3,4,5-tetrahydro-1h-3-benzazepines |
| LU65954A1 (cg-RX-API-DMAC7.html) | 1972-08-25 | 1974-03-07 | ||
| US4210749A (en) | 1974-11-12 | 1980-07-01 | Pennwalt Corporation | Substituted 1,2,4,5-tetrahydro-3H,3 benzazepines |
| SE7510988L (sv) | 1975-10-01 | 1977-04-02 | Draco Ab | Nya farmaceutiskt aktiva foreningar |
| US4111957A (en) | 1977-02-02 | 1978-09-05 | Smithkline Corporation | Substituted 1-thienyl and furyl-2,3,4,5-tetrahydro-1H-3-benzazepine compounds |
| US4108989A (en) | 1977-04-01 | 1978-08-22 | Smithkline Corporation | 2,3,4,5-tetrahydro-1h-3-benzazepine-7,8-diones |
| DE2758001A1 (de) | 1977-12-24 | 1979-07-12 | Hoechst Ag | Cephalosporinderivate und verfahren zu ihrer herstellung |
| CA1090797A (en) | 1978-06-20 | 1980-12-02 | Kenneth G. Holden | Substituted 1-thienyl and furyl-2,3,4,5-tetrahydro-1h- 3-benzazepine compounds |
| AU515236B2 (en) | 1978-06-26 | 1981-03-26 | Smithkline Corporation | Substituted-1-thienyl and furyl-2,3,4,5-tetrahydro-14-3 benzazepine derivatives |
| ZA792785B (en) | 1978-07-07 | 1980-08-27 | Smithkline Corp | Mercapto substituted-2,3,4,5-tetrahydro-1h-3-benzazepines |
| IE50355B1 (en) | 1979-10-20 | 1986-04-02 | Wyeth John & Brother Ltd | Morpholine derivatives |
| US4477378A (en) | 1980-02-05 | 1984-10-16 | Schering Corp. | Esters of substituted 8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines |
| EP0080779B1 (en) | 1981-11-27 | 1986-07-16 | Smithkline Beckman Corporation | 3-benzazepines as alpha-2 antagonists |
| FR2525603A1 (fr) | 1982-04-27 | 1983-10-28 | Adir | Benzoazacycloalkyl-spiro-imidazolinines, leur preparation et leur application en therapeutique |
| US4988690A (en) | 1982-06-14 | 1991-01-29 | Hoechst-Roussel Pharmaceuticals Inc. | 1-aryloxy-2,3,4,5-tetrahydro-3-benzazepines and anti-depressant use thereof |
| DE3418270A1 (de) | 1984-05-17 | 1985-11-21 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue aminotetralinderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| US4541954A (en) | 1984-09-05 | 1985-09-17 | Smithkline Beckman Corporation | Method for preparing 6-chloro-N-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine |
| EP0204349A3 (de) | 1985-06-01 | 1990-01-03 | Dr. Karl Thomae GmbH | Neue heteroaromatische Aminderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| GB8610668D0 (en) | 1986-05-01 | 1986-06-04 | Pfizer Ltd | Anti-arrhythmia agents |
| US4762845A (en) | 1986-05-21 | 1988-08-09 | Abbott Laboratories | 7-(3-Substituted imino-1-pyrrolidinyl)-quinolone-3-carboxylic acids |
| EP0285287A3 (en) | 1987-03-23 | 1990-08-16 | Smithkline Beecham Corporation | 3-benzazepine compounds for use in treating gastrointestinal motility disorders |
| ZA882080B (en) | 1987-03-27 | 1989-04-26 | Schering Corp | Substituted benzazepines,their preparation and pharmaceutical compositions containing them |
| US5247080A (en) | 1987-03-27 | 1993-09-21 | Schering Corporation | Substituted benzazepines useful as intermediates for producing pharmaceutically active compounds |
| US5015639A (en) | 1987-03-27 | 1991-05-14 | Schering Corporation | Substituted benzazepines, their preparation and pharmaceutical compositions containing them |
| WO1988007858A1 (en) | 1987-04-09 | 1988-10-20 | Smithkline Beckman Corporation | Sulfinyl and sulfonyl substituted 3-benzazepines |
| US4957914A (en) | 1987-05-15 | 1990-09-18 | Syntex (U.S.A.) Inc. | 1,9-alkano-bridged-2,3,4,5-tetrahydro-1H-3-benzazepines |
| DK107688D0 (da) | 1988-03-01 | 1988-03-01 | Novo Industri As | Carbaminsyreestere af substituerede 7-hydroxy-2,3,4,5-tetrahydro-1h-3-benzazepiner |
| US5422355A (en) | 1989-06-02 | 1995-06-06 | John Wyeth & Brother, Limited | Composition for treating depression with (N-heteroaryl)alkylamines |
| US5178786A (en) | 1989-08-04 | 1993-01-12 | The Lubrizol Corporation | Corrosion-inhibiting compositions and functional fluids containing same |
| MTP1076B (en) | 1990-01-12 | 1991-09-30 | Ciba Geigy Ag | Hemihydrate |
| EP0513174B1 (en) | 1990-02-02 | 1995-08-16 | Schering Corporation | 4,5-cycloalkano-3-benzazepin-7-ol-derivatives and their use |
| CA2037162A1 (en) | 1990-03-12 | 1991-09-13 | Steven Howard Shaber | Heterocyclicacetonitriles and fungicidal use |
| AU8201591A (en) | 1990-06-15 | 1992-01-07 | Schering Corporation | 8-lower alkyl-5-cycloalkyl or 5-cycloalkenyl substitued benzazepines and pharmaceutical compositions containing them |
| US5275915A (en) | 1991-06-05 | 1994-01-04 | Dainippon Ink And Chemicals, Inc. | Developer for light-sensitive material |
| PT100602A (pt) | 1991-06-21 | 1993-09-30 | Smithkline Beecham Plc | Uso de derivados de tetra-hidrobenzazepinas, derivados de tetra-hidrobenzazepinas,sua preparacao e composicoes farmaceuticas que os contem |
| GB9116824D0 (en) | 1991-08-05 | 1991-09-18 | Smithkline Beecham Corp | Chemical compounds |
| US5472712A (en) * | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
| EP0558824A1 (en) | 1992-02-04 | 1993-09-08 | Duphar International Research B.V | Method for the preparation of vicinal aminoalcohols and optically active O-protected derivatives thereof |
| US5241065A (en) | 1992-02-25 | 1993-08-31 | Schering Corporation | 2,3,4,5-tetrahydro-1h-3-benzazepines having anti-psychotic activity |
| JPH05339263A (ja) | 1992-06-08 | 1993-12-21 | Wakunaga Pharmaceut Co Ltd | ジヒドロピリジン誘導体 |
| JPH06298746A (ja) | 1993-04-19 | 1994-10-25 | Showa Denko Kk | 環状イミド酸エステルの製造法 |
| AU7177694A (en) | 1993-06-23 | 1995-01-17 | Cambridge Neuroscience, Inc. | Sigma receptor ligands and the use thereof |
| US5387685A (en) | 1993-07-16 | 1995-02-07 | American Cyanamid Co | MDR reversal agents |
| GB9322976D0 (en) | 1993-11-08 | 1994-01-05 | Pfizer Ltd | Therapeutic agents |
| DE4419315A1 (de) | 1994-06-01 | 1995-12-07 | Merckle Gmbh | Heteropyrrolizinverbindungen und deren Anwendung in der Pharmazie |
| DE4419247A1 (de) | 1994-06-01 | 1995-12-07 | Merckle Gmbh | Sulfonylierte Pyrrolizincarbonsäureamide und deren Anwendung in der Pharmazie |
| DE4419246A1 (de) | 1994-06-01 | 1995-12-07 | Merckle Gmbh | Heteroarylsubstituierte Pyrrolizinverbindungen und deren Anwendung in der Pharmazie |
| DE4427838A1 (de) | 1994-08-05 | 1996-02-08 | Thomae Gmbh Dr K | Kondensierte Azepinderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| DE4429079A1 (de) | 1994-08-17 | 1996-02-22 | Thomae Gmbh Dr K | Cyclische Harnstoffderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| JPH08134048A (ja) | 1994-11-08 | 1996-05-28 | Sumitomo Chem Co Ltd | オキサゾリン類の製造法 |
| DE19510566A1 (de) | 1995-03-23 | 1996-09-26 | Kali Chemie Pharma Gmbh | Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| GB9508622D0 (en) | 1995-04-28 | 1995-06-14 | Pfizer Ltd | Therapeutic agants |
| JPH0930960A (ja) | 1995-07-18 | 1997-02-04 | Takasago Internatl Corp | 真菌感染症治療剤 |
| JPH0987258A (ja) | 1995-09-28 | 1997-03-31 | Sumitomo Chem Co Ltd | オキサゾリン類、その製造方法およびそれを用いる不斉シクロプロパンカルボン酸類の製造方法 |
| CA2190708A1 (en) | 1995-12-08 | 1997-06-09 | Johannes Aebi | Aminoalkyl substituted benzo-heterocyclic compounds |
| US5892116A (en) | 1996-01-03 | 1999-04-06 | Georgetown University | Gelators |
| US5925651A (en) | 1996-04-03 | 1999-07-20 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5691362A (en) | 1996-06-05 | 1997-11-25 | Schering-Plough Corporation | Substituted benzene-fused hetero- and carbocyclics as nuerokinin antagonists |
| JP2001501172A (ja) | 1996-08-15 | 2001-01-30 | スミスクライン・ビーチャム・コーポレイション | Ｉｌ―８レセプターアンタゴニスト |
| US5908830A (en) | 1996-10-31 | 1999-06-01 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes and obesity |
| AU6290998A (en) | 1997-03-07 | 1998-09-29 | Novo Nordisk A/S | 4,5,6,7-tetrahydro-thieno{3,2-c}pyridine derivatives, their preparation and use |
| US5795895A (en) | 1997-06-13 | 1998-08-18 | Anchors; J. Michael | Combination anorexiant drug therapy for obesity using phentermine and an SSRI drug |
| AUPP020297A0 (en) | 1997-11-05 | 1997-11-27 | University Of Melbourne, The | A novel receptor, and compounds which bind thereto |
| DE69941777D1 (de) | 1998-03-10 | 2010-01-21 | Ono Pharmaceutical Co | Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten |
| CA2325741C (en) | 1998-03-26 | 2007-05-08 | Santen Pharmaceutical Co., Ltd. | Urea derivatives having tnf- .alpha. production inhibitory effects |
| EP0987235B1 (en) | 1998-08-25 | 2003-03-12 | MERCK PATENT GmbH | Method for the conversion of arenes or alkenes with iodoalkenes, aryl iodides or arenediazonium salts |
| US20080103179A1 (en) * | 2006-10-27 | 2008-05-01 | Tam Peter Y | Combination Therapy |
| US20080255093A1 (en) | 1999-06-14 | 2008-10-16 | Tam Peter Y | Compositions and methods for treating obesity and related disorders |
| ATE254614T1 (de) | 1999-08-06 | 2003-12-15 | Hoffmann La Roche | Tetrahydro-benzo(d)azepine und deren verwendung als metabotrope glutamatrezeptor-antagonisten |
| EP1074549B1 (en) | 1999-08-06 | 2003-11-19 | F. Hoffmann-La Roche Ag | Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors |
| JP2001076413A (ja) | 1999-09-06 | 2001-03-23 | Sony Corp | フレキシブル磁気ディスク用ヘッドスライダー |
| US6403657B1 (en) | 1999-10-04 | 2002-06-11 | Martin C. Hinz | Comprehensive pharmacologic therapy for treatment of obesity |
| DE10003708A1 (de) | 2000-01-28 | 2001-08-02 | Solvent Innovation Gmbh | Neuartige chirale ionische Flüssigkeiten und Verfahren zu ihrer Darstellung in enantiomerenreiner oder enantiomerenangereicherter Form |
| US7157466B2 (en) | 2000-06-30 | 2007-01-02 | Smithkline Beecham (Cork) Limited | Quinazoline ditosylate salt compounds |
| AU2303402A (en) | 2000-11-14 | 2002-05-27 | Smithkline Beecham Plc | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) |
| DE10057751A1 (de) | 2000-11-22 | 2002-05-23 | Bayer Ag | Neue Carbamat-substituierte Pyrazolopyridinderivate |
| GB0030710D0 (en) | 2000-12-15 | 2001-01-31 | Hoffmann La Roche | Piperazine derivatives |
| JPWO2002074746A1 (ja) | 2001-03-16 | 2004-07-08 | 山之内製薬株式会社 | ベンゾアゼピン誘導体 |
| US6825198B2 (en) | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
| AU2002356525A1 (en) | 2001-09-24 | 2003-04-07 | Elan Pharmaceuticals, Inc. | Substituted amines for the treatment of neurological disorders |
| DK1448235T3 (da) * | 2001-11-30 | 2007-07-02 | Pfizer Prod Inc | Orale, farmaceutiske sammensætninger af 5,8,14-triaza-tetracyclo[10.3.1.0(2,11).0(4.9)]-hexadeca-2(11),3,5,7,9-pentaen med kontrolleret frigivelse |
| EP1456178A1 (en) | 2001-12-21 | 2004-09-15 | Smithkline Beecham Plc | 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment of cns disorders |
| AU2002367323A1 (en) | 2001-12-28 | 2003-07-24 | Bayer Pharmaceuticals Corporation | Benzothieno (3,2- |
| CA2473740A1 (en) | 2002-01-18 | 2003-07-31 | David Solow-Cordero | Methods of treating conditions associated with an edg receptor |
| WO2003077847A2 (en) | 2002-03-12 | 2003-09-25 | Merck & Co., Inc. | Substituted amides |
| US6953787B2 (en) | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
| WO2003086303A2 (en) | 2002-04-12 | 2003-10-23 | The University Of Chicago | Farnesoid x-activated receptor agonists |
| US7105505B2 (en) | 2002-04-18 | 2006-09-12 | Schering Corporation | Benzimidazole derivatives useful as histamine H3 antagonists |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| GB0224557D0 (en) | 2002-10-22 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| DE10261131A1 (de) | 2002-12-20 | 2004-07-01 | Grünenthal GmbH | Substituierte 5-Aminomethyl-1H-pyrrol-2-carbonsäureamide |
| US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| BRPI0411470A (pt) | 2003-06-17 | 2006-07-11 | Arena Pharm Inc | derivados de benzazepina úteis para o tratamento de doenças associadas com o receptor de 5ht2c |
| EA016485B1 (ru) * | 2003-06-17 | 2012-05-30 | Арена Фармасьютикалз, Инк. | Способы получения 3-бензазепинов |
| EP1644347A1 (en) | 2003-06-20 | 2006-04-12 | Arena Pharmaceuticals, Inc. | N-PHENYL-PIPERAZINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT sb 2C /sb RECEPTOR ASSOCIATED DISEASES |
| TW200510324A (en) | 2003-08-11 | 2005-03-16 | Lilly Co Eli | 6-(2,2,2-trifluoroethylamino)-7-chiloro-2, 3, 4, 5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist |
| WO2005042490A1 (en) | 2003-10-22 | 2005-05-12 | Arena Pharmaceuticals, Inc. | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases |
| US20080009478A1 (en) | 2003-10-22 | 2008-01-10 | Arena Pharmaceuticals, Inc. | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases |
| PT1720836E (pt) | 2004-02-25 | 2014-07-16 | Lilly Co Eli | 2,3,4,5-tetra-hidro-1h-benzo[d]azepinas 6-substituídas como agonistas do recetor 5-ht2c |
| SE0401871D0 (sv) | 2004-07-15 | 2004-07-15 | Glucogene Medical Hfm Ab | New compositions |
| CA2575928A1 (en) | 2004-08-02 | 2006-02-09 | Genmedica Therapeutics Sl | Compounds for inhibiting copper-containing amine oxidases and uses thereof |
| US8178077B2 (en) | 2004-10-19 | 2012-05-15 | Reverse Proteomics Research Institute Co., Ltd. | Drug development target protein and target gene, and method of screening |
| NZ555981A (en) | 2004-12-21 | 2011-01-28 | Arena Pharm Inc | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride |
| CN102631349A (zh) | 2004-12-23 | 2012-08-15 | 艾尼纳制药公司 | 5HT2c受体调节剂组合物和使用方法 |
| MY148521A (en) | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
| ZA200711123B (en) * | 2005-06-27 | 2009-08-26 | Biovail Lab Int Srl | Modified-release formulations of a bupropion salt |
| KR20150013941A (ko) * | 2006-02-16 | 2015-02-05 | 아나코르 파마슈티칼스 인코포레이티드 | 항염증제로서 보론함유 소분자 |
| WO2007120517A2 (en) | 2006-04-03 | 2007-10-25 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates related thereto |
| WO2008019996A2 (en) * | 2006-08-14 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Formulations of flibanserin and method for manufacturing the same |
| WO2008061226A2 (en) * | 2006-11-17 | 2008-05-22 | Supernus Pharmaceuticals Inc. | Sustained-release formulations of topiramate |
| ES2522587T3 (es) | 2006-12-05 | 2014-11-17 | Arena Pharmaceuticals, Inc. | Procesos para preparar (R)-8-cloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzacepina e intermedios de la misma |
| JP2010514828A (ja) | 2007-01-04 | 2010-05-06 | プロシディオン・リミテッド | ピペリジンｇｐｃｒアゴニスト |
| EP2164324B1 (en) | 2007-06-15 | 2014-08-13 | University Of Florida Research Foundation | Therapeutic compounds |
| WO2009080691A2 (en) * | 2007-12-20 | 2009-07-02 | Neurosearch A/S | Pharmaceutical composition comprising tesofensine or its analogue and an anti-obesity compound |
| WO2009097416A1 (en) | 2008-01-29 | 2009-08-06 | Vanda Pharmaceuticals, Inc. | Imidazolylalkyl- pyridines as dbh inhibitors |
| CN102015591B (zh) | 2008-03-04 | 2014-01-29 | 艾尼纳制药公司 | 制备与5-ht2c激动剂(r)-8-氯-1-甲基-2，3，4，5-四氢-1h-3-苯并氮杂卓相关的中间体的方法 |
| WO2009123992A1 (en) | 2008-03-31 | 2009-10-08 | Metabolex, Inc. | Oxymethylene aryl compounds and uses thereof |
| BRPI0914891A2 (pt) | 2008-06-20 | 2015-11-24 | Metabolex Inc | agonistas de aril gpr119 e usos dos mesmos |
| MX2011002558A (es) | 2008-09-10 | 2011-04-26 | Boehringer Ingelheim Int | Terapia de combinacion para el tratamiento de diabetes y estados relacionados. |
| TWI478712B (zh) * | 2008-09-30 | 2015-04-01 | Astellas Pharma Inc | 釋控性醫藥組成物 |
| WO2010045417A2 (en) * | 2008-10-16 | 2010-04-22 | Metabolous Pharmaceuticals, Inc. | Combination therapies for the treatment of obesity |
| US20100285125A1 (en) * | 2009-05-07 | 2010-11-11 | Padma Venkitachalam Devarajan | Delivery system for poorly soluble drugs |
| CN102648170A (zh) | 2009-06-18 | 2012-08-22 | 艾尼纳制药公司 | 制备5-ht2c受体激动剂的方法 |
| AU2010264720A1 (en) | 2009-06-24 | 2011-12-08 | Boehringer Ingelheim International Gmbh | New compounds, pharmaceutical composition and methods relating thereto |
| WO2011153206A1 (en) * | 2010-06-02 | 2011-12-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 5-ht2c receptor agonists |
| CA2808890A1 (en) | 2010-09-01 | 2012-03-08 | Arena Pharmaceuticals, Inc. | Administration of lorcaserin to individuals with renal impairment |
| US20130267500A1 (en) | 2010-09-01 | 2013-10-10 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level |
| JP2013539470A (ja) | 2010-09-01 | 2013-10-24 | アリーナ ファーマシューティカルズ， インコーポレイテッド | ロルカセリンと光学活性な酸との塩 |
| SG10201506873WA (en) | 2010-09-01 | 2015-10-29 | Arena Pharm Inc | Fast-dissolve dosage forms of 5-ht2c agonists |
| CN103189053A (zh) * | 2010-09-01 | 2013-07-03 | 艾尼纳制药公司 | 用于体重控制的5-ht2c激动剂的调节释放剂型 |
| CA2808904A1 (en) | 2010-09-01 | 2012-03-08 | Arena Pharmaceuticals, Inc. | Non-hygroscopic salts of 5-ht2c agonists |
| CN102126988A (zh) | 2010-12-17 | 2011-07-20 | 张家港瀚康化工有限公司 | 4-(4-氯苯基)-2-溴甲基-2-苯基丁腈的制备方法 |
| CA2886875A1 (en) | 2012-10-09 | 2014-04-17 | Arena Pharmaceuticals, Inc. | Method of weight management |
-
2011
- 2011-08-31 CN CN2011800525606A patent/CN103189053A/zh active Pending
- 2011-08-31 KR KR1020187030466A patent/KR20180118801A/ko not_active Ceased
- 2011-08-31 CA CA3050049A patent/CA3050049A1/en not_active Abandoned
- 2011-08-31 EP EP18200702.1A patent/EP3485878A1/en not_active Withdrawn
- 2011-08-31 JP JP2013527255A patent/JP6272695B2/ja not_active Expired - Fee Related
- 2011-08-31 SG SG10201506874UA patent/SG10201506874UA/en unknown
- 2011-08-31 US US13/820,107 patent/US20130315994A1/en not_active Abandoned
- 2011-08-31 EP EP11755504.5A patent/EP2611427B1/en active Active
- 2011-08-31 SG SG2013015599A patent/SG188362A1/en unknown
- 2011-08-31 CA CA2808912A patent/CA2808912C/en not_active Expired - Fee Related
- 2011-08-31 ES ES11755504T patent/ES2704455T3/es active Active
- 2011-08-31 AU AU2011296003A patent/AU2011296003B2/en not_active Ceased
- 2011-08-31 CN CN201710915541.0A patent/CN107669687A/zh active Pending
- 2011-08-31 KR KR1020137008319A patent/KR101913442B1/ko not_active Expired - Fee Related
- 2011-08-31 WO PCT/US2011/049914 patent/WO2012030927A2/en not_active Ceased
-
2013
- 2013-02-20 IL IL22482913A patent/IL224829B/en active IP Right Grant
-
2016
- 2016-01-25 JP JP2016011493A patent/JP2016056211A/ja active Pending
-
2017
- 2017-02-10 US US15/429,221 patent/US10226471B2/en active Active
- 2017-09-19 JP JP2017179402A patent/JP2017214437A/ja not_active Withdrawn
-
2019
- 2019-01-07 US US16/241,337 patent/US10463676B2/en active Active
- 2019-07-03 JP JP2019124572A patent/JP2019163336A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013536857A5 (cg-RX-API-DMAC7.html) | ||
| JP6226916B2 (ja) | 医薬組成物 | |
| JP2013539470A5 (cg-RX-API-DMAC7.html) | ||
| JP2013536858A5 (cg-RX-API-DMAC7.html) | ||
| NZ264774A (en) | Use of fluoxetine, venlafaxine, milnacipran and duloxetine with a synergist in pharmaceutical compositions | |
| RU2007140348A (ru) | Способы и композиции для лечения заболеваний цнс | |
| JP2009536176A5 (cg-RX-API-DMAC7.html) | ||
| TW200812586A (en) | Use of flibanserin for the treatment of post-menopausal sexual desire disorders | |
| WO2005123074A1 (en) | Use of a compound in the treatment of sleep disorders | |
| JP2013536859A5 (cg-RX-API-DMAC7.html) | ||
| WO2015185011A1 (zh) | 喹啉衍生物用于治疗甲状腺癌的方法和用途以及用于治疗甲状腺癌的药物组合物 | |
| CN101252932B (zh) | 用于一天给药一次的曲唑酮组合物 | |
| WO2009142428A2 (en) | Pharmaceutical composition for the treatment of premature ejaculation | |
| WO1997006792A1 (en) | Potentiation of serotonin response | |
| JP2004525940A (ja) | 火照りの処置のためのデュロキセチン | |
| CN101990427A (zh) | 米格列奈及二甲双胍的复合制剂及其制造方法 | |
| WO2004096202A1 (en) | Pharmaceutical formulation comprising anti-obesity agent and acidulant | |
| WO2011112161A1 (en) | Extended release thiocolchicoside tablets | |
| TW383222B (en) | Pharmaceutical composition of bicycloheptane derivatives | |
| JP7270901B2 (ja) | 男性の避妊のための非ホルモン性組成物および方法 | |
| JP2006520764A (ja) | 子供による過剰な食物摂取を低減するためのプラミペキソール | |
| CN102283834B (zh) | 一种含奥利司他的药物组合物及用途 | |
| TWI324513B (en) | New association between agomelatine and a noradrenaline reuptake inhibitor, and pharmaceutical compositions containing it | |
| TW201626990A (zh) | 含有褪黑激素和舍曲林的口服複合錠劑 | |
| TW200940049A (en) | Associations for obtaining medicaments for the treatment of bipolar disorders |